Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

3SBio Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

Trading Report for (SSRX). A detailed report, including free correlated market analysis, and updates.

Detailed Trading Report for SSRX. Entry levels, target prices, and risk controls are integral. In addition, free market anal...

27 Sep 2016 Stock Traders Daily 5 $20.00

Thomson Reuters Stock Report - 3SBio Inc (1530-HK)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

25 Sep 2016 Thomson Reuters Stock Report 11 $25.00

3SBio Inc. (1530) - Financial and Strategic SWOT Analysis Review

3SBio Inc. (1530) - Financial and Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is a biotechnology companies that...

19 Sep 2016 GlobalData 71 $300.00

Wright Investors Service Comprehensive Report for 3sbio Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

08 Sep 2016 Wright Reports 64 $75.00

3SBio Inc. (1530) - Financial and Strategic SWOT Analysis Review

3SBio Inc. (1530) - Financial and Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is a biotechnology companies that...

06 Jun 2016 GlobalData 71 $300.00

Thomson Reuters Stock Report - 3SBio Inc (1530-HK)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 11 $25.00

3SBio Inc. (1530) - Strategic SWOT Analysis Review

3SBio Inc. (1530) - Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is one of the leading biotechnology companies i...

02 Mar 2016 GlobalData 56 $300.00

京 華 山 一 [ 三 生 製 藥 (1530 HK) - 未予評級 :生物製藥業領導欲透過收購促發展 ]

最新發展 我們與三生製藥的管理層舉行了投資者會議,其為中國領先的生物製藥商。 催化劑 創新藥特比澳為主要增長點。旗艦藥特比澳的15年度上半年收入增長37.8%,佔期內總收入37%。作為國家一類新藥,特比澳與化療引起血小板減少症(CIT)及免...

22 Feb 2016 Core Pacific - Yamaichi International (H.K.) Limited 3 $12.00

Core Pacific - Yamaichi [3SBio (1530 HK) : NOT RATED - Biopharm leader looking for acquisition to drive growth](2016/02/19)

What’s New We had an investor relation meeting with 3S Bio, a major biopharm company in China. Catalyst Innovative drug ...

19 Feb 2016 Core Pacific - Yamaichi International (H.K.) Limited 3 $35.00